You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Following the launch of its urine-based Qsant assay later this year, the firm plans to develop updated versions of it with new biomarkers for different disease indications.
After nearly a year in development, the firm's rapid antigen test will be submitted by the end of March for a prescription-use claim.
The researchers at the Royal College of Surgeons Ireland recently received €1.3 million from Wellcome Trust to support the development of the blood-based test.
The company said that the test, which detects IgG antibodies against SARS-CoV-2, can be used to measure immune responses to the virus and vaccines.
VolitionRx, which develops epigenetic-based blood tests for cancer and other diseases, said it will use the proceeds of the offering for general corporate purposes.
Nirmidas' antibody test can be used with serum and plasma samples, as well as fingerstick whole blood samples in a point-of-care setting.
Based on the results of the new studies, the Norwegian company is positioning its calprotectin test as an alternative to conventional ELISAs.
The firm is developing a test to determine interleukin-6 levels for SARS-CoV-2 patients and a rapid antigen test.
The ELISA-based test has shown 98.8 percent sensitivity and 99.6 percent specificity for detecting SARS-CoV-2 specific IgG against two virus antigens.
The assay is the first SARS-CoV-2 neutralizing antibody test to receive Emergency Use Authorization from the FDA.